Multiple Sclerosis :: Update on Tysabri in multiple sclerosis patients
Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that new data from the TOUCH Prescribing Program? and TYGRIS safety study confirm the safety profile from previous clinical studies of TYSABRI? (natalizumab). Also presented at the 59th annual meeting of the American Academy of Neurology in Boston, MA were extension study data that showed that TYSABRI has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis (MS) patients treated for up to three years.